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CONCLUSION
The CRISPR/Cas9 system is an innovative and reliable way to create novel transgenic cellular systems which can be used in vivo and in vitro. These 
experiments optimized a CRISPR/Cas9 editing mechanism that is time and cost effective. This process limits the pleiotropic effects due to position effects, 
multiple insertions, as well as time restrictions faced when performing gene integration.
By constructing the scaffolding for the in vitro transcriptions, and using the T7 Transcription Kit, the amount of time it would normally take for cells to run 
through the process naturally is restricted. This enhanced system allots for a short time requirement for an otherwise lengthy and complex mechanism. By using 
this approach and pairing it with what is known about the intron based “safe harbor” ROSAβ26, cells were transfected with a gene of interest, or target 
sequence. This target sequence is screened for through flow cytometry and by looking for an expression of a fluorescent protein from a mKate plasmid.  Once 
screened, data showed <2.5% positive cells in all control samples, mKate plasmid without CRISPR activity produced 13.8% positive red cells, and a slightly 
greater, 17%, of positive cells when CRISPR at solely the ROSA locus was active. Further analysis showed an increase in fluorescence by 10%-30% of those cells 
transfected with a ROSA sg-RNA and an mKate sg-RNA, compared to those cells with a single sg-RNA, as well as a slight increase of 5%-10% above the 
fluorescence levels of the far-red fluorescent mKate plasmid with no sg-RNAs. The most efficient integration of the reporter gene was found in samples 
containing sgRNA targeting both the genomic locus and plasmid, specifically R1 and M1 combination. This data in turn suggests that linearized mKate fluorescent 
plasmid improves integration into the genome.
Future analysis will include a T7 endonuclease screening system, which will act as a secondary validation that the CRISPR/Cas9 system created does in fact 
work. Additionally future research will focus on application of this method for new transgene incorporation into the ROSA locus, additional cell lines, and altered 
sgRNA loci for knocking out genes. Once this system has reached a satisfactory and completely optimized level of gene integration it can be used in vivo to assist 
in the alteration of embryonic stem cells and help create new transgenic lines with ease. 
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METHODOLOGY
BACKGROUND
The CRISPR-Cas system is a defense and regulatory mechanism which bacteria have evolutionarily acquired to cope with a 
number of the diverse stressors within their environment. Host bacteria use this to protect against other microorganisms by 
incorporating short sequences from the invader’s genome into its own (5). These sequences are distinguished by clustered 
regularly interspaced short palindromic repeats (CRISPRs). These CRISPRs are transcribed into short RNAs, and lead a 
multifunctional Cas-protein to distinguish and cleave other extraneous genomic material as an adaptive immunological response 
to outside antagonists (3). This research uses the CRISPR-Cas9 mechanism to develop an effective and reproducible technique to 
generate targeted alterations to the genome of mouse cells.
The ROSAβ26 (ROSA) is a locus in mice that is widely used for constitutive, ubiquitous gene expression, as well as used as a 
target for various reporter genes through genomic insertions (2). This site is considered to be a “safe harbor” locus, which allows 
for several advantages when producing a targeted transgenic model. Specifically, this ROSA site allows for transgene integration, 
single copy insertion, cis-regulatory elements, and versatility with transgenic modeling without alteration  of the phenotype (4). 
The ROSA site is located within the  first intron of the gene and can be targeted by homologous recombination. Using this site 
enables ubiquitous expression of insertions and is not prone to gene-silencing effects, as other sites are, or a decrease in cell 
viability. By combining the CRISPR/Cas9 machinery with this ROSA site, the possibility for easy and consistent gene editing is a
possibility. By using the Cas9 cutting mechanism and the CRISPR recognition site that is constructed through sg-RNAs and in vitro
transfection, an insertion of a target gene can be made within the ROSA locus with no disruption of other valuable cell processes.
ABSTRACT
The CRISPR-Cas system is an adaptive immune system found in bacteria which helps protect against the invasion of other microorganisms. This system induces double stranded breaks at precise genomic loci (1) in which repairs are initiated and insertions 
of a target are completed in the process. This mechanism can be used in eukaryotic cells in combination with sgRNAs (1) as a tool for genome editing. By using this CRISPR-Cas system, in addition to the “safe harbor locus,” ROSAβ26, the incorporation of 
a target gene into a site that is not susceptible to gene silencing effects can be achieved through few simple steps. PCR amplification of the target genes , ROSA26 and mKate2, with a sgRNA scaffold and T7 promoter followed by in vitro transcription aim 
to produce an RNA product. This sgRNA product can be run through a digestion with Cas9 to validate cleavage of the genomic ROSA DNA template or mKate plasmid. Osteoblast mouse cells are transfected and labeled through partial uptake by the 
CRISPR mechanism, by cutting in the ROSA loci and repairing with pieces of the fluorescent mKate2 plasmid. These cells were measured via flow cytometry to give a percentage of red cells. This data shows the scaffolding construct created is targeted by 
the Cas9 endonuclease and through homologous repair the cells will incorporate the mKate2 target gene in vitro in MC3T3 mouse cells. 
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Protocol:
1. Design 3 sgRNA targeting the ROSA26 locus in 
the mouse genome and 2 sgRNA targeting 
mKate2 (Figure  1)
2. Construction of sgRNA-scaffold-target* via 
PCR and  TAQ Polymerase (55oC)
3. In vitro Transcription using Ambion 
mMessage mMachine T7 Ultra Kit (3)
4. RNA Recovery via LiCl precipitation 
5. In vitro digestion with Cas9 nuclease to 
validate sgRNA site-specific DNA recognition 
and cleavage of DNA Template.
6. Transfection of gRNA, Cas9, and mKate2
plasmid into mouse osteoblast (MC3T3) cells. 
7. Flow Cytometry for validation of integration 
of mKate2 into ROSA26 through fluorescence.
NOTE: Validation of  step 2: sgRNA construct and step 3: T7 
transcription via gel electrophoresis (Figure 3)
Figure 2: Flowchart of the sgRNA-scaffold-target 
construction and CRISPR/Cas9 mechanism for genomic 
insertion.
Figure 4: Brightfield microscopy (top) and 
red fluorescent microscopy (bottom) of 
MC3T3 mouse pre-osteoblast cells. Cells 
imaged 48 hours post-transfection.
Cells only pMkate2-N ROSA+pMkate2-N
Figure 5: Flow cytometry results showing the 
distribution of mKate2 integration. The x-axis denotes 
fluorescent intensity and y-axis denotes quantity of cells. 
Populations within the gate represent successful 
genomic integration. This data suggests increased 
integration of mKate2 from the CRISPR/Cas9 system 
inducing double stranded breaks in both the genomic 
and plasmid DNA. 
M
2
M
1
Ø
R1 R2 R3
Figure 3: Gel Electrophoresis UV imaging 
for validation of T7 Transcription (left) and 
Cas9  endonuclease activity on the ROSA26 
loci and mKate2 plasmid (right)
Figure 1: Schematic of the ROSA26 locus (left) and the mKate2 plasmid (right) as well as primer locations on those sites. 
*
Figure 6: Analysis of flow cytometry 
showing the percent of red cells in each 
sample as compared to the whole cell 
count recorded. Where samples with both 
ROSA and mKate are being compared to 
the positive controls containing the mKate 
plasmid and negative control containing 
only cells with no plasmid.
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